Harvard Bioscience Reports Q1 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy HBIO?
Source: Newsfilter
- Revenue and Margin: Q1 2026 revenues reached $20.8 million, slightly down from $21.8 million in Q1 2025, while gross margin improved from 56% to 59%, indicating a successful shift towards a higher-margin product mix that is expected to drive future profitability.
- Net Loss Improvement: The net loss for Q1 2026 was $3.4 million, significantly lower than the $50.3 million loss in Q1 2025, which included a $48 million goodwill impairment, reflecting the company's progress in cost control and operational efficiency.
- Manufacturing Consolidation Progress: The company is on track with its manufacturing consolidation, which is expected to yield significant efficiencies and cost savings, laying a solid foundation for future growth.
- Full-Year Guidance Reaffirmed: Harvard Bioscience reaffirms its full-year guidance for 2026, anticipating significant revenue growth in the second half driven by higher-margin new product sales, with expected revenue growth between 2% and 4% and adjusted gross margins between 58% and 60%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HBIO
Wall Street analysts forecast HBIO stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.565
Low
2.00
Averages
2.00
High
2.00
Current: 5.565
Low
2.00
Averages
2.00
High
2.00
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harvard Bioscience Reports Q1 2026 Financial Results
- Revenue and Margin: Q1 2026 revenues reached $20.8 million, slightly down from $21.8 million in Q1 2025, while gross margin improved from 56% to 59%, indicating a successful shift towards a higher-margin product mix that is expected to drive future profitability.
- Net Loss Improvement: The net loss for Q1 2026 was $3.4 million, significantly lower than the $50.3 million loss in Q1 2025, which included a $48 million goodwill impairment, reflecting the company's progress in cost control and operational efficiency.
- Manufacturing Consolidation Progress: The company is on track with its manufacturing consolidation, which is expected to yield significant efficiencies and cost savings, laying a solid foundation for future growth.
- Full-Year Guidance Reaffirmed: Harvard Bioscience reaffirms its full-year guidance for 2026, anticipating significant revenue growth in the second half driven by higher-margin new product sales, with expected revenue growth between 2% and 4% and adjusted gross margins between 58% and 60%.
See More
Harvard Bioscience Q1 2026 Earnings Call Insights
- Stable Revenue Performance: Harvard Bioscience reported Q1 revenue of $20.8 million, aligning with the company's guidance of $20 million to $22 million, although it declined from $21.8 million in Q1 2025 primarily due to lower sales from academic institutions in the Americas and distributors in APAC.
- New Product Growth Drivers: The sales growth from the new product innovation pipeline, including Mesh MEA, BTX Electroporation, and SoHo Telemetry products, is expected to deliver double-digit revenue growth for the full year 2026, further solidifying the company's leadership in the translational science market.
- Strengthened Leadership Team: The appointment of Dave Panzarella as Senior Vice President of Commercial, with 30 years of industry experience, is anticipated to drive overall revenue expansion and sales of the translational science platforms, reflecting the company's confidence in future growth.
- Projected Savings from Initiatives: Management expects Project Viking to generate $3 million in savings in 2027 and $4 million annually thereafter, indicating a strategic commitment to optimizing operations and cost control.
See More
Harvard Bioscience Q1 2026 Financial Results and Guidance
- Disappointing Earnings: Harvard Bioscience (HBIO) reported a Q1 2026 non-GAAP EPS of -$0.33, missing expectations by $0.30, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company generated $20.76 million in revenue for the quarter, a 4.6% year-over-year decrease, falling short of expectations by $0.44 million, reflecting weak market demand that could negatively impact future performance.
- Margin Improvement: Despite the revenue drop, the gross margin for Q1 was 59%, up from 56% in Q1 2025, suggesting progress in cost control and product pricing strategies.
- Future Outlook: The company reaffirms its full-year 2026 guidance, anticipating revenue growth of 2% to 4% in the second half, driven by high-margin new product lines, demonstrating management's confidence in future recovery.
See More
Harvard Bioscience Announces Upcoming Investor Events
- Investor Event Schedule: Harvard Bioscience's CEO John Duke and CFO Mark Frost will participate in upcoming investor events, scheduled for May 21 and May 28, 2026, showcasing the company's advancements in life sciences.
- Sidoti Micro Cap Conference: This event will take place on May 21, where Harvard Bioscience will conduct a fireside chat at 11:30 AM ET, likely attracting significant investor interest and enhancing the company's visibility in the capital markets.
- Benchmark Healthcare Call: The virtual conference on May 28 will provide investors with direct interaction opportunities with company executives, enhancing transparency and fostering investor confidence in the company's future prospects.
- Live Webcast and Replay: The Sidoti fireside chat will be streamed live on Harvard Bioscience's Investor Relations website, with an archived replay available post-event, ensuring that investors who cannot attend live can still access critical information.
See More
Harvard Bioscience to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: Harvard Bioscience plans to release its financial results for the quarter ending March 31, 2026, before the market opens on May 12, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time, requiring analysts to register in advance to receive dial-in numbers and a unique PIN, ensuring participants can ask questions and obtain information smoothly.
- Webcast Information: Participants can access the audio-only webcast through the events and presentations section of the investor website, further enhancing interaction and information sharing with investors.
- Company Background: Harvard Bioscience focuses on the development and sale of technologies for life science applications, serving a diverse clientele that includes academic institutions and pharmaceutical companies, highlighting its significant position and broad influence in the industry.
See More
Harvard Bioscience Q4 2025 Earnings Call Insights
- Strong Financial Performance: Harvard Bioscience reported Q4 2025 revenue of $23.7 million with a gross margin of 60% and adjusted EBITDA of $3.8 million, reflecting a 27% year-over-year growth, indicating successful transformation towards higher-margin product lines.
- Strategic Consolidation Plan: The company announced the closure of the Holliston facility, consolidating operations into Minneapolis and European centers, expected to save $3 million by 2027, enhancing operational efficiency and resource optimization.
- Positive Outlook: CFO Mark Frost projected low single-digit revenue growth and high single-digit adjusted EBITDA growth for 2026, primarily driven by higher-margin new product introductions, demonstrating confidence in the translational science market.
- Governance Changes: The appointment of new CFO Mark Frost and four new board members signifies a strengthening of the governance structure, aimed at supporting the company's strategic transformation and sustained growth.
See More
Harvard Bioscience Reports Q1 2026 Financial Results
- Revenue and Margin: Q1 2026 revenues reached $20.8 million, slightly down from $21.8 million in Q1 2025, while gross margin improved from 56% to 59%, indicating a successful shift towards a higher-margin product mix that is expected to drive future profitability.
- Net Loss Improvement: The net loss for Q1 2026 was $3.4 million, significantly lower than the $50.3 million loss in Q1 2025, which included a $48 million goodwill impairment, reflecting the company's progress in cost control and operational efficiency.
- Manufacturing Consolidation Progress: The company is on track with its manufacturing consolidation, which is expected to yield significant efficiencies and cost savings, laying a solid foundation for future growth.
- Full-Year Guidance Reaffirmed: Harvard Bioscience reaffirms its full-year guidance for 2026, anticipating significant revenue growth in the second half driven by higher-margin new product sales, with expected revenue growth between 2% and 4% and adjusted gross margins between 58% and 60%.
See More
Harvard Bioscience Q1 2026 Earnings Call Insights
- Stable Revenue Performance: Harvard Bioscience reported Q1 revenue of $20.8 million, aligning with the company's guidance of $20 million to $22 million, although it declined from $21.8 million in Q1 2025 primarily due to lower sales from academic institutions in the Americas and distributors in APAC.
- New Product Growth Drivers: The sales growth from the new product innovation pipeline, including Mesh MEA, BTX Electroporation, and SoHo Telemetry products, is expected to deliver double-digit revenue growth for the full year 2026, further solidifying the company's leadership in the translational science market.
- Strengthened Leadership Team: The appointment of Dave Panzarella as Senior Vice President of Commercial, with 30 years of industry experience, is anticipated to drive overall revenue expansion and sales of the translational science platforms, reflecting the company's confidence in future growth.
- Projected Savings from Initiatives: Management expects Project Viking to generate $3 million in savings in 2027 and $4 million annually thereafter, indicating a strategic commitment to optimizing operations and cost control.
See More
Harvard Bioscience Q1 2026 Financial Results and Guidance
- Disappointing Earnings: Harvard Bioscience (HBIO) reported a Q1 2026 non-GAAP EPS of -$0.33, missing expectations by $0.30, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company generated $20.76 million in revenue for the quarter, a 4.6% year-over-year decrease, falling short of expectations by $0.44 million, reflecting weak market demand that could negatively impact future performance.
- Margin Improvement: Despite the revenue drop, the gross margin for Q1 was 59%, up from 56% in Q1 2025, suggesting progress in cost control and product pricing strategies.
- Future Outlook: The company reaffirms its full-year 2026 guidance, anticipating revenue growth of 2% to 4% in the second half, driven by high-margin new product lines, demonstrating management's confidence in future recovery.
See More
Harvard Bioscience Announces Upcoming Investor Events
- Investor Event Schedule: Harvard Bioscience's CEO John Duke and CFO Mark Frost will participate in upcoming investor events, scheduled for May 21 and May 28, 2026, showcasing the company's advancements in life sciences.
- Sidoti Micro Cap Conference: This event will take place on May 21, where Harvard Bioscience will conduct a fireside chat at 11:30 AM ET, likely attracting significant investor interest and enhancing the company's visibility in the capital markets.
- Benchmark Healthcare Call: The virtual conference on May 28 will provide investors with direct interaction opportunities with company executives, enhancing transparency and fostering investor confidence in the company's future prospects.
- Live Webcast and Replay: The Sidoti fireside chat will be streamed live on Harvard Bioscience's Investor Relations website, with an archived replay available post-event, ensuring that investors who cannot attend live can still access critical information.
See More
Harvard Bioscience to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: Harvard Bioscience plans to release its financial results for the quarter ending March 31, 2026, before the market opens on May 12, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time, requiring analysts to register in advance to receive dial-in numbers and a unique PIN, ensuring participants can ask questions and obtain information smoothly.
- Webcast Information: Participants can access the audio-only webcast through the events and presentations section of the investor website, further enhancing interaction and information sharing with investors.
- Company Background: Harvard Bioscience focuses on the development and sale of technologies for life science applications, serving a diverse clientele that includes academic institutions and pharmaceutical companies, highlighting its significant position and broad influence in the industry.
See More
Harvard Bioscience Q4 2025 Earnings Call Insights
- Strong Financial Performance: Harvard Bioscience reported Q4 2025 revenue of $23.7 million with a gross margin of 60% and adjusted EBITDA of $3.8 million, reflecting a 27% year-over-year growth, indicating successful transformation towards higher-margin product lines.
- Strategic Consolidation Plan: The company announced the closure of the Holliston facility, consolidating operations into Minneapolis and European centers, expected to save $3 million by 2027, enhancing operational efficiency and resource optimization.
- Positive Outlook: CFO Mark Frost projected low single-digit revenue growth and high single-digit adjusted EBITDA growth for 2026, primarily driven by higher-margin new product introductions, demonstrating confidence in the translational science market.
- Governance Changes: The appointment of new CFO Mark Frost and four new board members signifies a strengthening of the governance structure, aimed at supporting the company's strategic transformation and sustained growth.
See More
